After dose-finding and expansion within clinical studies, robust human biomarker and safety data are needed to provide a more complete assessment of what, if any, significant intratumoral changes are induced by GPR65 blockade within RCC lesions. The gene discussed is GPR65; the disease is renal cell carcinoma.